Misuse of Drugs (Medicinal Cannabis) Amendment Bill

  • enacted
4 Section 2 amended (Interpretation)


In section 2(1), insert in its their appropriate alphabetical order:

CBD product means a product that


contains cannabidiol; and


if it contains other cannabinoids usually found in cannabis, contains those cannabinoids in a quantity that, in total, constitutes no more than 2% of the total quantity of cannabinoids in the product; and


does not contain any other controlled drug; and


does not contain a psychoactive substance (as defined in section 9 of the Psychoactive Substances Act 2013)

terminal illness means an illness from which a person can reasonably be expected to die within 12 months

CBD product has the meaning given in section 2A

non-psychoactive THC analogue means a substance that


occurs naturally in cannabis; and


is not capable of inducing more than a minor psychoactive effect, by any means, in a person; and


has a structure substantially similar to that of


a tetrahydrocannabinol; or


an isomer, ester, or ether of a tetrahydrocannabinol; or


an ester or ether of an isomer of a tetrahydrocannabinol; or


a salt of any substance described in subparagraphs (i) to (iii)


In section 2(1), definition of controlled drug analogue, after paragraph (c), insert:


a non-psychoactive THC analogue


After section 2(1A), insert:


In this Act, a person requires palliation if, in the opinion of a medical practitioner or nurse practitioner, the person has an advanced progressive life-limiting condition and is nearing the end of their life.